View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Telenor ASA: 1 director

A director at Telenor ASA maiden bought 3,436 shares at 173.800NOK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

ABGSC Food & Beverage Research ... (+2)
  • ABGSC Food & Beverage Research
  • Mikkel Kousgaard Rasmussen
ABGSC Food & Beverage Research ... (+2)
  • ABGSC Food & Beverage Research
  • Mikkel Kousgaard Rasmussen
ABGSC Services Research ... (+3)
  • ABGSC Services Research
  • Julia Sundvall
  • Simon Jönsson
 PRESS RELEASE

Coloplast A/S - Opdateret finanskalender 2025-26

Coloplast A/S - Opdateret finanskalender 2025-26 Venligst se vedlagte pdf.  Opdatering af datoer i finanskalenderen Coloplast har opdateret datoerne i selskabets finanskalender vedrørende offentliggørelsen af årsregnskabet for 2025/26 samt afholdelsen af den ordinære generalforsamling 2026. De opdaterede datoer er som følger: Årsregnskabsmeddelelse for 2025/26 og Årsrapport 2025/26: ændret fra 5. november 2026 til 3. november 2026Ordinær generalforsamling 2026: ændret fra 3. december 2026 til 1. december 2026 For yderligere information og kalenderinvitationer til kommende beg...

 PRESS RELEASE

Coloplast A/S - Updated Financial Calendar 2025-26

Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026.  The updated dates are as follows: Financial Statements for the full year 2025/26 and Annual Report 2025/26: changed from November 5, 2026 to November 3, 2026Annual General Meeting 2026: changed from December 3, 2026 to December 1, 2026 For more information and calendar invitations for upcoming events, please visit:   Kind...

ABGSC Services Research ... (+3)
  • ABGSC Services Research
  • Julia Sundvall
  • Simon Jönsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Russell Waller
  • Russell Waller

Telenor (Neutral, TP: NOK 160, -7%) post Q4 25 model update – Impressi...

In this note, we update our model and thoughts following the Q4 results incorporating conference call feedback and compare our new estimates to guidance and consensus.

Russell Waller
  • Russell Waller

Telenor (Neutral, TP: NOK 150, -7%) Q4 25: Good results, new Buyback ...

Telenor has reported a good set of Q4 numbers, issued solid guidance for FY26, and announced a new 7% (over 3 years) buyback, that should help it shrug off the recent negative Telia-ICE RAN sharing news (HERE). We downgraded to Neutral in July (HERE) due to insufficient upside to be Buy, and because we saw better value elsewhere in the sector, and we were worried about dividend cover given rising Asian costs. Selling out of Thailand (HERE) helps repair the B/S and supports sentiment. As things s...

Jan Frederik Slijkerman ... (+5)
  • Jan Frederik Slijkerman
  • Jeroen van den Broek
  • Jesse Norcross
  • Nadège Tillier
  • Timothy Rahill
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Telecom Operators Research ... (+3)
  • ABGSC Telecom Operators Research
  • Åsne Holsen
  • Øystein Elton Lodgaard
 PRESS RELEASE

Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26

Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26   2025/26 Delårsrapport, 1. kvartal 2025/261. oktober 2025 - 31. december 2026 Coloplast leverede i 1. kvartal en organisk vækst på 6% og en EBIT vækst1 i faste valutakurser på 3%. Den rapportede omsætning i danske kroner steg 0%, hvilket afspejler en negativ valutaeffekt på 4 procentpoint. Afkast af investeret kapital2 var på 15%. • Organisk vækst pr. område: Stomi 4 %, Kontinens 7 %, Stemme og Respiratorisk Pleje 8 %, Wound & Tissue Repair 5 % og Urologi 8 %.• Svag start i Stomi, som forventet, drevet af negativ vækst i Kina og høj baseli...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch